... challenges. Immune effector cell-associated neurotoxicity syndrome (ICANS) is one of the major and severe CAR-T cell-related complications, developing in about 10–30% of patients [ 2‒5 ]. CAR-T cells are increasingly applied for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL), even...

... system lymphoma Diffuse large B-cell lymphoma Zanubrutinib Cytarabine Bruton’s tyrosine kinase inhibitor Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non-Hodgkin lymphoma that accounts for approximately 4% of central nervous system neoplasms [ 1...

.... In this study, we investigated the incidence of GC-induced adrenal insufficiency in patients receiving intermittent short-term high-dose oral GC treatment for newly diagnosed diffuse large B-cell lymphoma. Cosyntropin stimulation test was used to assess adrenal function at study entry (baseline), at 2 months...

... to in the content or advertisements. 2023 Richter’s transformation Accelerated chronic lymphocytic leukemia Diffuse large B-cell lymphoma Novel agents Bruton tyrosine kinase inhibitor B-cell lymphoma-2 PD-1 Chimeric antigen receptor T cell There are currently three histological and clinical...

...Shuxin Xiao; Chuanbo Fan; Jinlong Ma; Hongwei Xue; Liqin Xu Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and a candidate therapeutic option for human cancers. However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma...

...Ho-Jin Shin; Do-Young Kim; JooSeop Chung; Kyung-Hwa Shin; Hyungi Lee Introduction: The effects of lymphocyte subtypes, including helper (Th), natural killer (NK), and regulatory (Treg) cells, and other T-cell subtypes on treatment outcomes in diffuse large B-cell lymphoma (DLBCL) patients...

...Pier Luigi Zinzani; Marco Bregni; Mario Spione; Manfred Mitterer; Gerardo Musuraca; Annamaria Bugli; Francesco Piazza; Antonello Pinto Introduction: Treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) represents a challenge for clinicians due to the lack of therapeutic...

...Marianna Gentilini; Beatrice Casadei; Alessandro Broccoli; Lisa Argnani; Michele Cavo; Pier Luigi Zinzani There is an unmet clinical need for elderly or unfit diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem cell transplantation. Lenalidomide is an immunomodulatory...

...Yang Xia; Xinlian Zhang MYC, as a powerful transcription factor, plays a vital role in various cancers. The clinical significance of MYC alterations in diffuse large B-cell lymphoma (DLBCL) has been investigated for a long time. In this study, we comprehensively summarize the different alterations...

... with diffuse large B-cell lymphoma (DLBCL). Methods: A total of 46 DLBCL patients treated with pre-ASCT were enrolled in the present study, and two methods, Deauville score and maximal standardized uptake value reduction (ΔSUV max ), were used to evaluate the PET/CT scans before transplantation. Results...

...TingBo Liu; LiHong Chen; Jie Pan; LiLi Pan; JianDa Hu; ZhongYou Ji Background: The International Prognostic Index (IPI) scoring system is the most widely used prognostic tool for diffuse large B-cell lymphoma (DLBCL); however, it fails to consistently identify patients with poor outcomes...

... liver nodularity, which led to the diagnosis of a primary liver diffuse large B-cell lymphoma. Discussion: We review the evidence supporting possible mechanisms of lymphomagenesis after successful hepatitis C therapy, particularly involving late “second-hit” mutations after viral-induced DNA damage...

...Reyad Dada Diffuse large B-cell lymphoma is an aggressive non-Hodgkin lymphoma subtype which requires immediate treatment. Standard treatment is usually a combined immune chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Since R-CHOP was approved...

...Francesco Malaspina; Cinzia Pellegrini; Beatrice Casadei; Lisa Argnani; Pier Luigi Zinzani Diffuse large B-cell lymphoma is the most frequent histology at diagnosis among non-Hodgkin B lymphomas and can be cured in 50-70% of cases after the first-line chemotherapy regimen. Patients who do...

... in diffuse large B-cell lymphoma (DLBCL) patients. Currently, the standard regimen is R-CHOP every 21 days. Methods: This is a phase II clinical trial of treatment with 6 cycles of R-CHOP-14 with pegfilgrastim support in 2 populations of previously untreated DLBCL patients aged ≥65 years (n = 73) or <65...

...Antica Duletić-Načinović; Vedrana Gačić; Toni Valković; Ksenija Lučin; Elizabeta Fišić; Marta Žuvić-Butorac; Irena Seili-Bekafigo; Nives Jonjić Background: Diffuse large B-cell lymphomas (DLBCL) are heterogeneous diseases, and the identification of additional DLBCL risk factors is especially...

...Chunhong Hu; Chao Deng; Wen Zou; Guangsen Zhang; Jingjing Wang Background: The current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP). The role of radiotherapy (RT) after complete response...

...Sung-Hoon Jung; Deok-Hwan Yang; Jae-Sook Ahn; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee We evaluated the relationship between serum lactate dehydrogenase (LDH) level with systemic inflammation score and survival in 213 patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP...

... patients with testicular lymphoma. One patient with diffuse large B-cell lymphoma (DLBCL) was lost to follow-up after diagnosis. Two patients with Burkitt's lymphoma had poor outcomes regardless of treatment. Thus, we analyzed the clinical features, treatments, and outcomes of 19 patients with DLBCL...

...S. Al-Humood; A. AlQallaf; S. Al-Shemmari; L. Al-Faris; B. Al-Ayadhy Epstein-Barr virus (EBV) has a pathogenic role in several lymphomas, including diffuse large B-cell lymphoma (DLBCL). EBV-associated genetic aberrations in DLBCL have not been fully characterized. The aim of this study...